Short-lasting unilateral XXXX with conjunctival injection and tearing syndrome: a review.

@entity1 @entity2682 @entity1640 @entity19425 @entity3303 @entity1771 @entity158 @entity10 @entity2812
The clinical features of short-lasting unilateral @entity10 attacks with conjunctival injection and tearing ( @entity19425 ) syndrome have been reviewed in 50 @entity1 reported in the English language literature. @entity19425 is a rare condition that predominates slightly in @entity1 . The mean age at onset is 50 years. It is characterized by strictly unilateral attacks centered on the orbital or periorbital regions, forehead, and temple. Generally, the @entity158 is severe and neuralgic in character. The usual duration ranges from 5 to 250 seconds, although the reported range of duration is 2 seconds to 20 minutes. Ipsilateral conjunctival injection and lacrimation are present in most, but not all @entity1 . Most @entity1 are thought to have no refractory periods and this has probably been unreported in the past. Episodic and chronic forms of @entity19425 exist. The attack frequency varies from less than one attack daily to more than 60 attacks per hour. The attacks are predominantly diurnal, although frequent nocturnal attacks can occur in some @entity1 . A functional magnetic resonance imaging study in @entity19425 has demonstrated @entity1640 activation. @entity19425 was thought to be highly refractory to treatment. However, recent open-label trials of @entity2812 , @entity2682 , @entity1771 , and intravenous @entity3303 have produced beneficial therapeutic responses. These results offer the promise of better treatments for this syndrome, but require validation in controlled trials.
